Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of “Buy” from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned a consensus rating of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $65.00.

ARCT has been the topic of several research analyst reports. BTIG Research began coverage on Arcturus Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $41.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday, February 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th.

Hedge Funds Weigh In On Arcturus Therapeutics

Several institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. increased its stake in shares of Arcturus Therapeutics by 54.6% during the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after acquiring an additional 36,714 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after purchasing an additional 712,650 shares in the last quarter. Empire Life Investments Inc. increased its position in Arcturus Therapeutics by 85.5% during the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after purchasing an additional 128,771 shares during the period. Hennion & Walsh Asset Management Inc. raised its stake in shares of Arcturus Therapeutics by 139.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock worth $1,393,000 after buying an additional 47,824 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Arcturus Therapeutics in the third quarter valued at approximately $191,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Performance

ARCT opened at $17.32 on Thursday. Arcturus Therapeutics has a one year low of $14.30 and a one year high of $45.00. The stock has a market capitalization of $469.20 million, a P/E ratio of -7.80 and a beta of 2.62. The business’s 50-day simple moving average is $16.97 and its 200-day simple moving average is $18.86.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.